TIGIT axis: novel immune checkpoints in anti-leukemia immunity

Hematologic malignancy evades immune-mediated recognition through upregulating various checkpoint inhibitory receptors (IRs) on several types of lymphocytes. Immunotherapies targeting IRs have provided ample evidence supporting regulating innate and adaptive immunity and obtaining clinical benefits....

Full description

Saved in:
Bibliographic Details
Published in:Clinical and experimental medicine 2023-06, Vol.23 (2), p.165-174
Main Authors: Qiu, Dan, Liu, Xiaxin, Wang, Wandi, Jiang, Xuan, Wu, Xiaofang, Zheng, Jiamian, Zhou, Kai, Kong, Xueting, Wu, Xiuli, Jin, Zhenyi
Format: Article
Language:English
Subjects:
Adaptive immunity
Antigens, Differentiation, T-Lymphocyte
Cancer immunotherapy
Hematology
Humans
Immune checkpoint inhibitors
Immunotherapy
Internal Medicine
Lymphocytes T
Malignancy
Medicine
Medicine & Public Health
Neoplasms - therapy
Oncology
Receptors, Immunologic
Review Article
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Hematologic malignancy evades immune-mediated recognition through upregulating various checkpoint inhibitory receptors (IRs) on several types of lymphocytes. Immunotherapies targeting IRs have provided ample evidence supporting regulating innate and adaptive immunity and obtaining clinical benefits. Newly described IRs have received considerable attention and are under investigation in cancer immunotherapy. Specifically, T cell immunoglobulin and ITIM domain is a novel inhibitory checkpoint receptor, and its immune checkpoint axis includes additional receptors such as CD96 and CD226, which are very promising targets. However, how the dynamics and functions of these receptor networks remain unknown, this review addresses the recent findings of the relevance of this complex receptor-ligand system and discusses their potential approaches in translating these preclinical findings into novel clinical agents in anti-leukemia immunotherapy.
ISSN:1591-9528
1591-8890
1591-9528
DOI:10.1007/s10238-022-00817-0